Inside CAR-T Therapy For Ovarian Cancer with Anixa Biosciences' Amit Kumar, Ph.D.

Cell & Gene: The Podcast

English - April 28, 2022 08:00 - 18 minutes - 12.9 MB - ★★★★★ - 35 ratings
Life Sciences Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Pivoting to Allogeneic CAR-T Therapies with Celyad Oncology’s CMO, Dr. Charlie Morris

Next Episode: Gene Therapy's Commercial Manufacturing Issues with Encoded Therapeutics' Andy Stober

We love to hear from our listeners. Send us a message.

Amit Kumar, Ph.D., President and CEO at Anixa Biosciences details the company’s progress on its Phase 1 trial for ovarian cancer. We also discuss why the company’s ovarian cancer program is integral for initial proof of concept for other solid tumor indications. He covers why CAR-T therapy uses an existing hormone/hormone receptor relationship to create a targeted approach to treat ovarian cancer. Dr. Kumar shares how the field of cell therapy may evolve in the short term, and much more.